Rigel Announces First Quarter 2017 Financial Results and Provides Company Update May 02, 2017 4:01pm EDT
Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States Apr 27, 2017 7:30am EDT
Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results Apr 25, 2017 7:30am EDT
Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update Mar 07, 2017 4:01pm EST
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results Feb 28, 2017 7:30am EST
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares Feb 03, 2017 4:01pm EST
